JP2009528065A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528065A5
JP2009528065A5 JP2008557419A JP2008557419A JP2009528065A5 JP 2009528065 A5 JP2009528065 A5 JP 2009528065A5 JP 2008557419 A JP2008557419 A JP 2008557419A JP 2008557419 A JP2008557419 A JP 2008557419A JP 2009528065 A5 JP2009528065 A5 JP 2009528065A5
Authority
JP
Japan
Prior art keywords
polynucleotide
seq
acta
listeria bacterium
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008557419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528065A (ja
JP5347135B2 (ja
Filing date
Publication date
Priority claimed from US11/395,197 external-priority patent/US7935804B2/en
Priority claimed from US11/396,216 external-priority patent/US20070207171A1/en
Application filed filed Critical
Priority claimed from PCT/US2007/005457 external-priority patent/WO2007103225A2/en
Publication of JP2009528065A publication Critical patent/JP2009528065A/ja
Publication of JP2009528065A5 publication Critical patent/JP2009528065A5/ja
Application granted granted Critical
Publication of JP5347135B2 publication Critical patent/JP5347135B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008557419A 2006-03-01 2007-03-01 遺伝子工学操作されたlisteriaおよびその使用方法 Expired - Fee Related JP5347135B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US77847106P 2006-03-01 2006-03-01
US60/778,471 2006-03-01
US78457606P 2006-03-21 2006-03-21
US60/784,576 2006-03-21
US11/395,197 US7935804B2 (en) 2006-03-01 2006-03-30 Engineered Listeria and methods of use thereof
US11/395,197 2006-03-30
US11/396,216 2006-03-30
US11/396,216 US20070207171A1 (en) 2006-03-01 2006-03-30 Engineered listeria and methods of use thereof
PCT/US2007/005457 WO2007103225A2 (en) 2006-03-01 2007-03-01 Engineered listeria and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2009528065A JP2009528065A (ja) 2009-08-06
JP2009528065A5 true JP2009528065A5 (enExample) 2010-04-15
JP5347135B2 JP5347135B2 (ja) 2013-11-20

Family

ID=38475431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557419A Expired - Fee Related JP5347135B2 (ja) 2006-03-01 2007-03-01 遺伝子工学操作されたlisteriaおよびその使用方法

Country Status (8)

Country Link
EP (2) EP1991263B8 (enExample)
JP (1) JP5347135B2 (enExample)
DK (1) DK1991263T3 (enExample)
ES (1) ES2532942T3 (enExample)
GB (1) GB2451014B (enExample)
PT (1) PT1991263E (enExample)
SI (1) SI1991263T1 (enExample)
WO (1) WO2007103225A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
ES2741730T3 (es) * 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011149852A1 (en) * 2010-05-23 2011-12-01 Aduro Biotech Methods and compositions using listeria for adjuvant treatment of cancer
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
ES2684684T3 (es) * 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
EP2825195A4 (en) 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
HK1213008A1 (zh) 2012-11-06 2016-06-24 艾杜罗生物科技公司 兼性减毒细菌种类及其制备和使用方法
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
HK1250731A1 (zh) 2015-04-13 2019-01-11 艾杜罗生物科技公司 用於治疗癌症的免疫原性融合蛋白
SG11201708360TA (en) * 2015-04-13 2017-11-29 Aduro Biotech Inc Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
EA201890149A1 (ru) 2015-06-26 2018-07-31 Сирус Корпорейшн Композиции криопреципитатов и способы их получения
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
HUE058657T2 (hu) 2016-06-23 2022-09-28 Jiangsu Hengrui Medicine Co Lag-3 antitest, antigénkötõ fragmentuma és gyógyszerészeti alkalmazása
AU2017382449B2 (en) 2016-12-23 2024-10-24 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
BR112019018273A2 (pt) 2017-03-03 2020-07-14 Cerus Corporation kits e métodos para preparação de composições de plaquetas inativadas por patógenos
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
BR112020010499A2 (pt) 2017-12-13 2020-11-24 Inovio Pharmaceuticals, Inc. vacinas de câncer de alvo de mesotelina e usos das mesmas
TWI821233B (zh) 2017-12-29 2023-11-11 美商西勒斯股份有限公司 用於處理生物流體之方法、藉由該方法製備之病原體去活生物流體、及用於處理生物流體之系統
CA3143213A1 (en) 2019-06-22 2020-12-30 Cerus Corporation Biological fluid treatment systems
WO2020264421A1 (en) 2019-06-28 2020-12-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551784B2 (en) 1989-06-07 2003-04-22 Affymetrix Inc Method of comparing nucleic acid sequences
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
CA2241604C (en) 1996-01-05 2010-03-30 Ira Pastan Mesothelium antigen and methods and kits for targeting it
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
DK1351709T3 (da) 2000-06-09 2005-01-31 Us Gov Health & Human Serv Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
PT1592441E (pt) 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン,インコーポレーテッド リステリアに基づくEphA2ワクチン
EP1708741B1 (en) * 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20060135457A1 (en) * 2004-08-13 2006-06-22 Yvonne Paterson Methods for constructing antibiotic resistance free vaccines
ES2684749T3 (es) * 2004-08-13 2018-10-04 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia a antibióticos

Similar Documents

Publication Publication Date Title
JP2009528065A5 (enExample)
Ridpath et al. Delayed onset postvaccinal mucosal disease as a result of genetic recombination between genotype 1 and genotype 2 BVDV
ES2255181T3 (es) Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
JP2011529077A (ja) C型肝炎の治療のための組成物および方法
JP2014504851A5 (enExample)
ES2685922T3 (es) Vacunas poxvirales mejoradas
Babin et al. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP
CN1251042A (zh) 广泛反应性的dr限制性表位的鉴定
JP2017513502A5 (enExample)
JP2020520662A5 (enExample)
CN112063592A (zh) 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用
JP2005509420A5 (enExample)
JP2007537722A (ja) 癌胎児性抗原融合タンパク質及びその使用
JP2003533232A5 (enExample)
JP2008545393A5 (enExample)
JP6313215B2 (ja) 組み換え酵母を用いた、定義された抗原に対する防御的体液性免疫応答の生成による予防接種
CN100471957C (zh) 用于免疫治疗的腺病毒载体
JP6213969B2 (ja) 免疫原性ポリペプチド表層発現ビフィズス菌
EP2483409B1 (en) LACTOBACILLUS glyceraldehyde-3-phosphate dehydrogenase PROMOTERS AND USES THEREOF
JPWO2020243719A5 (enExample)
CN117535322A (zh) 具有异源抗原的活的减毒黄病毒
CN1471580A (zh) 含有外源性内表位的病毒颗粒
US20160324954A1 (en) Immunogenic compositions for inhibiting hepatitis d virus
JP2007518405A5 (enExample)
WO2004096288A2 (es) Método para la obtencion de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores.